NT-proBNP levels predict mortality in patients with acute decompensated and de novo heart failure: Study

Based on the findings, the researchers reported the following findings:

• NT-proBNP levels were significantly lower in patients with DNHF than in those with ADHF (median 4213 vs. 5523 ng/L).
• Compared to patients with DNHF, patients with ADHF had a significantly worse prognosis for 1-year all-cause mortality (adjusted hazard ratio (HR) = 1.46).
• A higher NT-proBNP level was associated with higher 1-year all-cause mortality for both heart failure types (adjusted HR = 2.00 in ADHF; adjusted HR = 2.41 in DNHF).
• All-cause mortality risk was always higher in patients with ADHF than in those with DNHF for any given NT-proBNP level.

The authors conclude, "NT-proBNP had an important role as a prognostic factor in both DNHF and ADHF. However, as time passed ADHF had poorer outcomes than DNHF." "ADHF patients had higher risks than DNHF patients at any level of NT-proBNP."

Reference:

Kim SE, Cho DH, Son JW, Kim JY, Kang SM, Cho MC, Lee HY, Choi DJ, Jeon ES, Yoo BS. Impact of NT-proBNP on prognosis of acute decompensated chronic heart failure versus de novo heart failure. Int J Cardiol. 2022 Jun 23:S0167-5273(22)01007-5. doi: 10.1016/j.ijcard.2022.06.055. Epub ahead of print. PMID: 35753618.